Previous 10 | Next 10 |
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Seeking Alpha wishes our subscribers a beautiful holiday weekend and a Happy Fourth of July! Wall Street Breakfast won't be published with markets closed o...
Kiromic BioPharma ([[KRBP]] -2.0%) has closed an 8M share public offering of common shares, raising $40M.The company also granted underwriters a 45-day option to purchase up to an additional 1.2M shares only to cover over-allotments.ThinkEquity acted as the sole book-runner.Kiromic plans to u...
Kiromic BioPharma, Inc. (Nasdaq: KRBP) (the “Company”), an immuno-oncology target discovery and gene-editing company with a proprietary artificial intelligence neural network platform (Diamond AI) that is used to develop novel oncology therapeutics, today announced the clo...
Kiromic BioPharma ([[KRBP]] -16.9%) has priced an underwritten public offering of 8M shares at $5 per share for gross proceeds of $40M.Kiromic has also granted underwriters a 45-day option to purchase up to an additional 1.2M shares of common stock.The ThinkEquity division of division of Ford...
Kiromic BioPharma, Inc. (Nasdaq: KRBP) (the “Company”), an immuno-oncology target discovery and gene-editing company with a proprietary artificial intelligence neural network platform (Diamond AI) that is used to develop novel oncology therapeutics, today announced the pri...
Kiromic Biopharma, Inc. (Nasdaq: KRBP) Kiromic is being recognized as a pioneer of immuno oncology with a presentation at the 4th Annual Next-Gen Immuno Oncology Congress in June 2021. At the conference, we will: -- Present our artificial intelligence (AI) predicted and sele...
Kiromic is being recognized as a pioneer of Gamma Delta T (GDT) cell therapy manufacturing and has been invited to present its off-the-shelf allogeneic CAR-T technology at the prestigious Gamma Delta T Cell Summit in July 2021. — April 2021. KRBP presented its manufacturing o...
Kiromic BioPharma (KRBP) announces the expansion of its in-house cGMP manufacturing facility to provide support to the company's clinical trials.The company also announces the appointment of Ignacio Núñez as its chief operating officer and manufacturing officer.Núñez has o...
Kiromic BioPharma, Inc. (Nasdaq: KRBP) — Expansion of in-house cGMP manufacturing facility to provide support to the Company's clinical trials. Therapeutic doses expected to be ready for first in-human dosing in 3Q-2021. — Mr. Ignacio Núñez, a 20-year ind...
Point Roberts, WA and Vancouver, BC - May 24, 2021 (Investorideas.com Newswire) Investorideas.com ( www.investorideas.com ), a global investor news source covering Artificial Intelligence (AI) brings you today's edition of The AI Eye - watching stock news, deal tracker and advanceme...
News, Short Squeeze, Breakout and More Instantly...
Kiromic BioPharma Inc. Company Name:
KRBP Stock Symbol:
OTCMKTS Market:
Kiromic BioPharma Inc. Website:
Enrollment in the Expansion Phase Expected to Commence in September Deltacel Safety Confirmed at Day 30 in Trial’s Fifth Patient; Efficacy Results on this Patient Expected in August Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company...
Follow-up Findings Show Stable Disease FDA and IRB Approve IND for a Single-Use, Single-Patient Treatment with Deltacel Fast Track Designation Request Submitted to FDA Complete Enrollment in Trial’s Second Cohort Expected in July Kiromic BioPharma, Inc. ...
Favorable Follow-up Findings Include Stable Disease and a 13% Decrease in Tumor Size Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable six-month follow-up results from the first patient enrolled in the Deltacel-01 Phase ...